164 related articles for article (PubMed ID: 37167707)
1. GLP-1 receptor agonist, liraglutide, protects podocytes from apoptosis in diabetic nephropathy by promoting white fat browning.
Wang J; Zhou Y; Long D; Wu Y; Liu F
Biochem Biophys Res Commun; 2023 Jul; 664():142-151. PubMed ID: 37167707
[TBL] [Abstract][Full Text] [Related]
2. The key role of a glucagon-like peptide-1 receptor agonist in body fat redistribution.
Zhao L; Zhu C; Lu M; Chen C; Nie X; Abudukerimu B; Zhang K; Ning Z; Chen Y; Cheng J; Xia F; Wang N; Jensen MD; Lu Y
J Endocrinol; 2019 Feb; 240(2):271-286. PubMed ID: 30530905
[TBL] [Abstract][Full Text] [Related]
3. Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy.
Shi S; Chen X; Yu W; Ke X; Ma T
Endocr Connect; 2023 Oct; 12(10):. PubMed ID: 37522848
[TBL] [Abstract][Full Text] [Related]
4. Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats.
Yamada S; Tanabe J; Ogura Y; Nagai Y; Sugaya T; Ohata K; Natsuki Y; Ichikawa D; Watanabe S; Inoue K; Hoshino S; Kimura K; Shibagaki Y; Kamijo-Ikemori A
Clin Exp Nephrol; 2021 Apr; 25(4):365-375. PubMed ID: 33409761
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation.
Sourris KC; Ding Y; Maxwell SS; Al-Sharea A; Kantharidis P; Mohan M; Rosado CJ; Penfold SA; Haase C; Xu Y; Forbes JM; Crawford S; Ramm G; Harcourt BE; Jandeleit-Dahm K; Advani A; Murphy AJ; Timmermann DB; Karihaloo A; Knudsen LB; El-Osta A; Drucker DJ; Cooper ME; Coughlan MT
Kidney Int; 2024 Jan; 105(1):132-149. PubMed ID: 38069998
[TBL] [Abstract][Full Text] [Related]
6. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
Somm E; Montandon SA; Loizides-Mangold U; Gaïa N; Lazarevic V; De Vito C; Perroud E; Bochaton-Piallat ML; Dibner C; Schrenzel J; Jornayvaz FR
Transl Res; 2021 Jan; 227():75-88. PubMed ID: 32711187
[TBL] [Abstract][Full Text] [Related]
7. The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients.
Imamura S; Hirai K; Hirai A
Tohoku J Exp Med; 2013 Sep; 231(1):57-61. PubMed ID: 24064677
[TBL] [Abstract][Full Text] [Related]
8. The impact of the glucagon-like peptide 1 receptor agonist liraglutide on the streptozotocin-induced diabetic mouse kidney proteome.
Liljedahl L; Pedersen MH; McGuire JN; James P
Physiol Rep; 2019 Feb; 7(4):e13994. PubMed ID: 30806030
[TBL] [Abstract][Full Text] [Related]
9. Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.
Hernández C; Bogdanov P; Corraliza L; García-Ramírez M; Solà-Adell C; Arranz JA; Arroba AI; Valverde AM; Simó R
Diabetes; 2016 Jan; 65(1):172-87. PubMed ID: 26384381
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide suppresses obesity and promotes browning of white fat via miR-27b
Wang X; Chen S; Lv D; Li Z; Ren L; Zhu H; Xie X; Liu Y
J Int Med Res; 2021 Nov; 49(11):3000605211055059. PubMed ID: 34772311
[TBL] [Abstract][Full Text] [Related]
11. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 and vitamin D: anti-inflammatory response in diabetic kidney disease in db/db mice and in cultured endothelial cells.
Einbinder Y; Ohana M; Benchetrit S; Zehavi T; Nacasch N; Bernheim J; Zitman-Gal T
Diabetes Metab Res Rev; 2016 Nov; 32(8):805-815. PubMed ID: 26991522
[TBL] [Abstract][Full Text] [Related]
13. GLP-1R Agonist Liraglutide Attenuates Inflammatory Reaction and Neuronal Apoptosis and Reduces Early Brain Injury After Subarachnoid Hemorrhage in Rats.
Tu XK; Chen Q; Chen S; Huang B; Ren BG; Shi SS
Inflammation; 2021 Feb; 44(1):397-406. PubMed ID: 32951103
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
Lovshin JA
Can J Diabetes; 2017 Oct; 41(5):524-535. PubMed ID: 28942790
[TBL] [Abstract][Full Text] [Related]
15. Liraglutide induced browning of visceral white adipose through regulation of miRNAs in high-fat-diet-induced obese mice.
Zhao L; Li W; Zhang P; Wang D; Yang L; Yuan G
Endocrine; 2024 Feb; ():. PubMed ID: 38378894
[TBL] [Abstract][Full Text] [Related]
16. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
Takashima S; Fujita H; Fujishima H; Shimizu T; Sato T; Morii T; Tsukiyama K; Narita T; Takahashi T; Drucker DJ; Seino Y; Yamada Y
Kidney Int; 2016 Oct; 90(4):783-96. PubMed ID: 27475229
[TBL] [Abstract][Full Text] [Related]
17. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets.
Le TDV; Fathi P; Watters AB; Ellis BJ; Besing GK; Bozadjieva-Kramer N; Perez MB; Sullivan AI; Rose JP; Baggio LL; Koehler J; Brown JL; Bales MB; Nwaba KG; Campbell JE; Drucker DJ; Potthoff MJ; Seeley RJ; Ayala JE
Mol Metab; 2023 Jun; 72():101718. PubMed ID: 37030441
[TBL] [Abstract][Full Text] [Related]
19.
Tan X; Zhu T; Zhang L; Fu L; Hu Y; Li H; Li C; Zhang J; Liang B; Liu J
Adipocyte; 2022 Dec; 11(1):120-132. PubMed ID: 35094659
[TBL] [Abstract][Full Text] [Related]
20. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
Chun JH; Butts A
JAAPA; 2020 Aug; 33(S8 Suppl 1):3-18. PubMed ID: 32756220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
